Koninklijke Philips (NYSE:PHG) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Koninklijke Philips (NYSE:PHG) from a buy rating to a hold rating in a research report released on Sunday morning.

PHG has been the subject of a number of other reports. Sanford C. Bernstein raised shares of Koninklijke Philips from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 18th. BNP Paribas raised shares of Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research report on Tuesday, February 25th. Finally, UBS Group raised shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a research report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Performance

NYSE:PHG opened at $22.10 on Friday. Koninklijke Philips has a twelve month low of $20.61 and a twelve month high of $31.57. The company has a current ratio of 1.28, a quick ratio of 0.79 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $23.79 and a 200-day moving average of $25.22. The firm has a market cap of $20.77 billion, a price-to-earnings ratio of 51.39, a price-to-earnings-growth ratio of 0.65 and a beta of 0.76.

Koninklijke Philips (NYSE:PHG) last announced its earnings results on Tuesday, May 6th. The technology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.14 by $0.13. Koninklijke Philips had a net margin of 2.11% and a return on equity of 10.97%. The company had revenue of $4.31 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the company posted $0.21 earnings per share. The business’s revenue for the quarter was down 1.0% on a year-over-year basis. Analysts forecast that Koninklijke Philips will post 1.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Koninklijke Philips

A number of institutional investors have recently modified their holdings of PHG. Colonial Trust Co SC raised its position in shares of Koninklijke Philips by 724.0% in the fourth quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company’s stock valued at $36,000 after purchasing an additional 1,238 shares during the period. Bessemer Group Inc. raised its position in shares of Koninklijke Philips by 2,935.4% in the first quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock valued at $51,000 after purchasing an additional 1,908 shares during the period. Farther Finance Advisors LLC raised its position in shares of Koninklijke Philips by 37.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company’s stock valued at $54,000 after purchasing an additional 582 shares during the period. Whipplewood Advisors LLC acquired a new stake in shares of Koninklijke Philips in the fourth quarter worth $55,000. Finally, Millstone Evans Group LLC acquired a new stake in shares of Koninklijke Philips in the fourth quarter worth $60,000. Institutional investors own 13.67% of the company’s stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.